A preliminary report on the role of somatostatin analogue (SMS 201-995) in the management of children with tall stature.
We have studied the effect of somatostatin analogue (SMS 201-995) given as a subcutaneous injection on the growth and growth hormone secretion in seven tall children (two male; five female). SMS 201-995 was given in doses of 37.5 or 50 micrograms on a once or twice-daily regimen. Growth velocity decreased from a pretreatment median of 8.3 cm/year (range 5.5-12.2) to 3.0 cm/year (range 0.2-4.5) after 6 months treatment (Wilcoxon, P = 0.02). In three of the children therapy was discontinued for the next 6 months with restoration of growth rate to pretreatment values in two of the three. Growth hormone secretion decreased as a result of SMS 201-995 therapy although one child needed a twice-daily regimen to achieve long-term suppression. Final height measurements were reduced in four of five patients with an overall reduction between 1.1 and 6.3 cm and no change in the other. No effects of treatment on fasting glucose and insulin, glycosylated haemoglobin or serum thyroxine concentrations were observed. These preliminary studies suggest that SMS 201-995 may have a role in the management of the growth of tall children but the optimum mode of administration remains to be established.
Hindmarsh
P C
PC
Endocrine Unit, Middlesex Hospital, London.
Pringle
P J
PJ
Di Silvio
L
L
Brook
C G
CG
D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D001827:Body Height; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy*; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D015282:Octreotide / Q000008:administration & dosage* / Q000627:therapeutic use; D013974:Thyroxine / Q000097:blood
D001786:Blood Glucose; D007328:Insulin; D013006:Growth Hormone; D013974:Thyroxine; D015282:Octreotide